NCT05212584 - CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions

Relapsed/Refractory, High Risk Hematologic MalignanciesT-ALL/Lymphoma

Interventions

BIOLOGICAL

CD7CAR T cells

CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.

Trial Locations (1)

Unknown

RECRUITING

Hebei Yanda Lu Daopei Hospital, Langfang